Humira Pen Adalimumab 40mg / 0.8ml is a prescription medicine that is used to treat several chronic inflammatory conditions, particularly rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, and plaque psoriasis. It is a biologic drug that mimics the function of human antibodies, thereby suppressing the immune system’s response that causes inflammation. Humira Pen Adalimumab is injected subcutaneously (under the skin) with a pen device.
The active ingredient of Humira Pen Adalimumab is adalimumab, which is a human monoclonal antibody that targets tumor necrosis factor-alpha (TNF-alpha). It is produced by recombinant DNA technology using mammalian cell fermentation. The medicine contains 40mg of adalimumab in 0.8ml of solution, along with other excipients like citric acid, mannitol, polysorbate 80, sodium citrate, and water for injection.
Humira Pen Adalimumab is used in the treatment of several chronic inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, and plaque psoriasis. It is also used in the treatment of other autoimmune disorders like ulcerative colitis and juvenile idiopathic arthritis. The medicine helps to alleviate the symptoms of these conditions, including joint pain, swelling, and stiffness, skin rash, and abdominal pain.
Usage and Dosage:
The medicine is available in a prefilled pen device that is used for subcutaneous injection. The recommended dose is 40mg every other week for adults with rheumatoid arthritis or psoriatic arthritis, or 40mg every week for ankylosing spondylitis, Crohn’s disease, or plaque psoriasis. For children with juvenile idiopathic arthritis, the dosage is based on weight. The injection site should be rotated every time to avoid localized skin reactions. The medicine should be administered by a healthcare professional or trained person.
The medicine should be stored in the refrigerator at 2°C to 8°C until the expiry date. Do not freeze, shake, or expose to heat or light. The pen should be kept away from children and pets.
Mechanism of action:
Humira Pen Adalimumab works by neutralizing TNF-alpha, which is a molecule that triggers inflammation in the body in response to various stimuli. TNF-alpha plays a crucial role in the pathogenesis of several inflammatory diseases, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, and plaque psoriasis. By blocking TNF-alpha, Humira Pen Adalimumab helps to reduce inflammation and its associated symptoms.
Humira Pen Adalimumab is contraindicated in patients with active tuberculosis, severe infections, or hypersensitivity to adalimumab or any of its excipients. It should not be used in patients with moderate to severe congestive heart failure. The medicine should be used with caution in patients with a history of malignancies, hepatitis B or C infections, or demyelinating disorders.
The most common side effects of Humira Pen Adalimumab include injection site reactions, headache, infections, sinusitis, and nausea. Serious side effects may include allergic reactions, infections, heart failure, blood disorders, liver problems, and nervous system disorders. Patients should seek immediate medical attention if they experience any signs of an allergic reaction or severe infection, such as fever, chills, or difficulty breathing. Long-term use of Humira Pen Adalimumab may increase the risk of developing certain cancers, including lymphoma. Patients should be monitored regularly for any signs of malignancy.